United European gastroenterology journal · 2026
The Associations Between Acid-Suppressive Drug Intake and Symptom Profiles in Functional Dyspepsia Patients Referred for Open-Access Endoscopy.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Janne Scheepers, Florencia Carbone, Hanne Matheussen, Karen Van den Houte, Jan Tack
Аннотация
BACKGROUND: Functional dyspepsia (FD) is characterised by postprandial fullness, early satiation, epigastric pain, or burning without structural abnormalities on upper endoscopy. Proton pump inhibitors (PPIs) are the preferred first-line therapy. Given that the diagnosis of FD is largely based on symptom assessment, it remains unclear whether acid-suppression meaningfully influences symptom presentation.
OBJECTIVE: This exploratory study aimed to determine the prevalence of acid-suppressive therapy (PPIs or H2 receptor antagonists (H2RAs)) among FD patients and to compare symptom patterns between patients with and without these treatments.
METHODS: In this single-centre, cross-sectional observational study, ambulatory patients referred for diagnostic upper endoscopy completed the Waiting Room Questionnaire (WRQ). Endoscopic findings were recorded, and FD was defined using Rome IV. Acid-suppression was defined as self-reported use of PPIs or H2RAs. Symptom frequency was compared between patients on and off therapy.
RESULTS: 1158 patients completed the WRQ; 27% fulfiled the criteria for FD. Among FD patients, 60% reported acid-suppressive therapy, similar to patients with endoscopic findings. FD patients receiving acid-suppression reported higher frequencies of early satiation (OR = 1.68, 95% CI 1.08-2.60), nausea (OR = 1.93, 95% CI 1.23-3.01), and epigastric pain (OR = 1.74, 95% CI 1.12-2.69). In subgroup analyses, therapy was associated with more frequent epigastric burning in postprandial distress syndrome (OR = 3.81, 95% CI 1.50-9.67) and higher frequencies of postprandial fullness (OR = 2.90, 95% CI 1.24-6.80) and early satiation (OR = 2.34, 95% CI 1.13-4.85) in the overlap subgroup.
CONCLUSIONS: FD is prevalent in open-access endoscopy, and acid-suppressive therapy is frequently used in this population. FD patients receiving acid-suppression reported slightly higher frequencies of several symptoms, highlighting the need to further explore these associations.
OBJECTIVE: This exploratory study aimed to determine the prevalence of acid-suppressive therapy (PPIs or H2 receptor antagonists (H2RAs)) among FD patients and to compare symptom patterns between patients with and without these treatments.
METHODS: In this single-centre, cross-sectional observational study, ambulatory patients referred for diagnostic upper endoscopy completed the Waiting Room Questionnaire (WRQ). Endoscopic findings were recorded, and FD was defined using Rome IV. Acid-suppression was defined as self-reported use of PPIs or H2RAs. Symptom frequency was compared between patients on and off therapy.
RESULTS: 1158 patients completed the WRQ; 27% fulfiled the criteria for FD. Among FD patients, 60% reported acid-suppressive therapy, similar to patients with endoscopic findings. FD patients receiving acid-suppression reported higher frequencies of early satiation (OR = 1.68, 95% CI 1.08-2.60), nausea (OR = 1.93, 95% CI 1.23-3.01), and epigastric pain (OR = 1.74, 95% CI 1.12-2.69). In subgroup analyses, therapy was associated with more frequent epigastric burning in postprandial distress syndrome (OR = 3.81, 95% CI 1.50-9.67) and higher frequencies of postprandial fullness (OR = 2.90, 95% CI 1.24-6.80) and early satiation (OR = 2.34, 95% CI 1.13-4.85) in the overlap subgroup.
CONCLUSIONS: FD is prevalent in open-access endoscopy, and acid-suppressive therapy is frequently used in this population. FD patients receiving acid-suppression reported slightly higher frequencies of several symptoms, highlighting the need to further explore these associations.